These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 31616641)

  • 1. Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets.
    Taylor OG; Brzozowski JS; Skelding KA
    Front Oncol; 2019; 9():963. PubMed ID: 31616641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A narrative review of research progress on drug therapies for glioblastoma multiforme.
    Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G
    Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
    Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards standardization of the parameters for opening the blood-brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models.
    Thombre R; Mess G; Kempski Leadingham KM; Kapoor S; Hersh A; Acord M; Kaovasia T; Theodore N; Tyler B; Manbachi A
    Front Oncol; 2022; 12():1072780. PubMed ID: 36873300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
    Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
    Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update.
    Hsu JF; Chu SM; Liao CC; Wang CJ; Wang YS; Lai MY; Wang HC; Huang HR; Tsai MH
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?
    Giles B; Nakhjavani M; Wiesa A; Knight T; Shigdar S; Samarasinghe RM
    Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma Multiforme-A Look at the Past and a Glance at the Future.
    King JL; Benhabbour SR
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma multiforme: State of the art and future therapeutics.
    Wilson TA; Karajannis MA; Harter DH
    Surg Neurol Int; 2014; 5():64. PubMed ID: 24991467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery.
    Brar HK; Jose J; Wu Z; Sharma M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
    Kim SS; Harford JB; Pirollo KF; Chang EH
    Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma.
    Cruz N; Herculano-Carvalho M; Roque D; Faria CC; Cascão R; Ferreira HA; Reis CP; Matela N
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Vascular Drug Delivery in Cerebral Cancer.
    Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
    Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Biomarkers for Immunotherapy in Glioblastoma.
    Mensali N; Inderberg EM
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
    Gutkin A; Cohen ZR; Peer D
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma.
    Galimberti C; Piepoli T; Letari O; Artusi R; Persiani S; Caselli G; Rovati LC
    Am J Cancer Res; 2021; 11(7):3558-3574. PubMed ID: 34354860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.